Genisphere Appoints New CEO, Thomas Bliss

HATFIELD, Pa., June 30, 2015 /PRNewswire/ -- Genisphere announced Tom Bliss has joined the company as CEO to help further develop Genisphere's therapeutics capabilities and portfolio. Mr. Bliss comes with a wealth of partnering experience, having spent much of the last 25 years in leadership positions at biopharmaceutical companies including Therakine, Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started his career in Investment Banking, with a focus on Technology and Biotech Corporate Finance. He graduated from Dartmouth College with a BA in English and Asian Studies (Mandarin), and completed his MBA at The Wharton School, University of Pennsylvania in Finance and Marketing.

Logo - http://photos.prnewswire.com/prnh/20150629/226697LOGO

Tom joins Genisphere as the Company pivots to focus more resources on its emerging therapeutic portfolio, having established its diagnostics business with key strategic partners. "I am excited to start a new challenge with Genisphere, and look forward to working with the team to develop and expand their pharmaceutical collaborations. I know Genisphere has already had substantial success demonstrating our unique 3DNA technology and I'm sure success will accelerate as additional data are generated." 

Dr. Robert Getts, Chief Science Officer, commented, "Tom's wealth of experience and industry knowledge has already made him a key addition to the Genisphere family. Our new innovations led us to look for an experienced leader for our team who will fit in with the company culture, and I'm sure he will make immediate positive contributions." James Kadushin, Chief Operating Officer, said, "I look forward to working with Tom. It is very fortunate that we were able to find someone with deep pharmaceutical development and partnering experience to fulfill this role."

About Genisphere
Genisphere LLC is a targeted drug delivery platform company. Genisphere's platform is a DNA-based nanotechnology called 3DNA®. 3DNA® nanocarriers are used to deliver drugs in a highly targeted manner. Genisphere's technology is IP-protected and fully customizable to deliver a variety of therapeutics including small drugs, biologics, and nucleic acids. 3DNA® nanostructures are composed entirely of DNA, engineered and cross-linked to form a stable architecture while maintaining the biocompatibility of the nucleic acid building blocks. Genisphere has been leveraging a collaborative model to advance its drug delivery platform, and continues to seek partnerships with biotechnology and pharmaceutical companies that could benefit from the company's platform technology. Genisphere is also advancing its own lead compounds based on the 3DNA® platform. For more information, please visit http://genisphere.com

For more information contact:

Dr. Robert Getts
Genisphere 
215-996-3027
Email

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genisphere-appoints-new-ceo-thomas-bliss-300106672.html

SOURCE Genisphere LLC

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.